Can biological signals explain mastocytosis symptoms?
NCT ID NCT07757893
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This study aims to understand how symptoms of indolent systemic mastocytosis relate to biological signals in the body. Researchers will collect samples and data from 25 participants over 12 weeks to see how different treatments affect these signals. The goal is to improve understanding of the condition and potentially guide more personalized care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could lead to better understanding of systemic mastocytosis, potentially improving symptom management and treatment personalization.
- What could go wrong
- This is a small, early-stage observational study. It may not produce definitive answers, and findings may not apply to all patients with the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT SYSTEMIC MASTOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug aims to tame rare mast cell disease
- Blood test may spare patients painful bone marrow biopsy
- Bone drug shows promise for rare mast cell disorder
- New antibody drug tested in patients with relapsed blood cancers
- New study tracks daily life with rare mast cell disorder
- New drug avapritinib under Real-World watch for mastocytosis relief